Altria Group, Inc.

Altria Group, Inc. (MO) Market Cap

Altria Group, Inc. has a market capitalization of $107.29B.

Financials based on reported quarter end 2025-12-31

Price: $64.17

β–Ό -0.77 (-1.19%)

Market Cap: 107.29B

NYSE Β· time unavailable

CEO: William F. Gifford Jr.

Sector: Consumer Defensive

Industry: Tobacco

IPO Date: 1985-07-01

Website: https://www.altria.com

Altria Group, Inc. (MO) - Company Information

Market Cap: 107.29B Β· Sector: Consumer Defensive

Altria Group, Inc., through its subsidiaries, manufactures and sells smokeable and oral tobacco products in the United States. The company provides cigarettes primarily under the Marlboro brand; cigars and pipe tobacco principally under the Black & Mild brand; and moist smokeless tobacco products under the Copenhagen, Skoal, Red Seal, and Husky brands, as well as provides on! oral nicotine pouches. It sells its tobacco products primarily to wholesalers, including distributors; and large retail organizations, such as chain stores. Altria Group, Inc. was founded in 1822 and is headquartered in Richmond, Virginia.

Analyst Sentiment

56%
Buy

Based on 14 ratings

Analyst 1Y Forecast: $64.38

Average target (based on 6 sources)

Consensus Price Target

Low

$47

Median

$66

High

$74

Average

$63

Downside: -1.8%

Price & Moving Averages

Loading chart...

πŸ“˜ Full Research Report

ℹ️

AI-Generated Research: This report is for informational purposes only.

πŸ“˜ Altria Group, Inc. (MO) β€” Investment Overview

🧩 Business Model Overview

Altria Group, Inc. operates as a holding company with a primary focus on tobacco and nicotine products, positioning itself as a leading U.S. manufacturer and marketer in this sector. Its core business is anchored by iconic cigarette brands, most notably Marlboro, alongside a growing portfolio of smokeless tobacco products, oral nicotine pouches, and emerging reduced-risk offerings. Altria’s customer base comprises adult consumers, predominantly in the United States, where it maintains a strong distribution and retail presence. The company leverages established relationships with wholesalers, retailers, and strategic partners to ensure wide product availability, while also exploring partnerships and investments in adjacent sectors such as cannabis and e-vapor.

πŸ’° Revenue Model & Ecosystem

Altria's revenue is derived primarily from the sale of finished consumer tobacco and nicotine products to wholesale distributors and large retail chains. Its model emphasizes direct sales in highly regulated environments, benefiting from strong pricing power and brand loyalty. Beyond cigarettes, revenue streams encompass smokeless tobacco, oral nicotine pouches, and partnerships or stakes in alternative nicotine delivery platforms, like electronic vaporizers. The company also pursues income from strategic investments and licensing arrangements, further diversifying its exposure across the broader consumer products and alternative sectors. Altria’s business ecosystem is deeply interlinked, with synergies between its various product lines and a focus on long-term consumer retention and lifecycle value.

🧠 Competitive Advantages

  • Brand strength: Altria's flagship brands, most notably Marlboro, command leading market share and significant consumer recognition, conferring enduring pricing and shelf-space advantages.
  • Switching costs: Consumer loyalty and habitual purchasing patterns create high switching costs, especially given the regulated product landscape and ingrained brand preferences.
  • Ecosystem stickiness: The complementary suite of combustible, smokeless, and emerging product formats helps retain customers within Altria’s ecosystem as consumption preferences evolve.
  • Scale + supply chain leverage: The company’s large-scale operations enable cost efficiencies, premium retailer relationships, and influence over supply chain logistics, supporting consistent margins even in a mature industry.

πŸš€ Growth Drivers Ahead

Several multi-year growth avenues are apparent for Altria. The conversion of adult smokers to potentially less harmful alternatives, such as oral nicotine pouches and vapor products, is a core strategic priority, aligning with shifting consumer trends and regulatory interests. Expansion into new product categories, investments in cannabis-related opportunities, and partnerships with innovative nicotine technology companies also represent strategic initiatives aimed at long-term relevance. Product innovation, premiumization, and pricing strategies provide additional levers for organic growth. Finally, ongoing cost optimization programs and supply chain digitization may further unlock operating efficiencies.

⚠ Risk Factors to Monitor

Altria operates in an environment of heightened regulatory scrutiny, where legislative shifts, tax increases, and advertising restrictions can impact demand dynamics and product innovation. Intensifying competitionβ€”both from incumbent peers and new entrants in reduced-risk categoriesβ€”poses risks to market share and margins. The decline in combustible cigarette volumes, potentially faster than anticipated, represents a persistent headwind. Other risks include reputational pressures, potential litigation, and challenges in successfully commercializing next-generation products or executing on diversification strategies.

πŸ“Š Valuation Perspective

The market tends to value Altria at a relative discount to more growth-oriented consumer staples peers, reflecting both the secular decline in traditional tobacco consumption and the regulatory uncertainties that cloud future earnings visibility. At the same time, consistent profitability, a history of significant shareholder capital returns, and strong brand equity support a defensive investment profile. The company’s valuation often embodies a tradeoff between cash yield stability and skepticism about long-term volume and diversification prospects.

πŸ” Investment Takeaway

For investors, Altria offers a classic case of a high-cash-flow, mature business with enduring brand strength but facing structural headwinds. The bull case rests on the company’s ability to leverage its brands, pricing power, and innovation initiatives to offset volume declines, supplemented by disciplined capital returns. The bear case emphasizes regulatory and social pressures, the challenges of achieving meaningful diversification, and ongoing product volume attrition. Ultimately, Altria can appeal to those seeking stable cash generation, but requires ongoing scrutiny of its transformation efforts and the evolving regulatory landscape.


⚠ AI-generated research summary β€” not financial advice. Validate using official filings & independent analysis.

Altria delivered solid FY25 results driven by pricing and margin expansion in smokeables and growth in smoke-free, notably ON!. Management advanced the smoke-free pipeline (ON PLUS authorizations, heated tobacco submissions) and expanded international pouches, while returning significant cash to shareholders. However, illicit disposable e‑vapor remains a major headwind, prompting a $1.3B e‑vapor impairment and a measured investment stance. FY26 EPS guidance of 2.5%–5.5% growth is weighted to the back half, supported by import/export initiatives and ON PLUS’s national launch, but assumes limited near-term enforcement impact and NJOY ACE not returning.

Growth

  • Adjusted diluted EPS +4.4% for FY25; FY26 guidance +2.5%–5.5%.
  • Smoke-free products now >50% of U.S. nicotine space; total nicotine volumes +~2% CAGR over 5 years.
  • ON! shipments +~11% to >177M cans in FY25; Q4 shipments >44M cans.
  • Middleton cigar shipments +4.2% in Q4 and +1.8% for FY25.
  • Smokeables net price realization +8.4% in FY25; segment margin +1.8 pp to 63.4%.

Business Development

  • FDA marketing granted orders for ON PLUS Mint, Wintergreen, Tobacco (6mg/9mg); 12mg under review.
  • Resumed ON PLUS shipments in FL, NC, TX; national launch planned in H1 2026.
  • Helix submitted PMTAs for six additional ON PLUS flavors across three strengths.
  • Horizon submitted combined PMTA/MRTPA for Plume device and Marlboro heated tobacco sticks.
  • Strategic collaboration with KT&G to advance international modern oral, U.S. non-nicotine innovation, and tobacco operating efficiencies.
  • International pouches (ON PLUS, Fumi) expanded to ~40,000 retail locations across 7 markets; 12 flavor variants.

Financials

  • Smokeable products adjusted OCI >$11B for FY25; margin 63.4% (+1.8 pp).
  • Q4 smokeables adjusted OCI βˆ’2.4%; margin 60.4% (βˆ’0.8 pp) due to higher manufacturing costs (import/export build-out).
  • Domestic cigarette volumes: βˆ’7.9% in Q4; βˆ’10% FY25 (βˆ’7% and βˆ’9.5% adjusted). Industry βˆ’6.5% in Q4; βˆ’8% FY.
  • Oral Tobacco Products adjusted OCI βˆ’4.6% in Q4; margin 64.5% (βˆ’5 pp). FY adjusted OCI +1.3%; margin 67.9% (+0.1 pp).
  • Oral segment reported shipment volumes: βˆ’6.3% Q4; βˆ’5.5% FY (adjusted βˆ’6.4%/βˆ’5.5%); segment retail share 29.6% Q4, 31.9% FY.
  • Marlboro retail share βˆ’1.5 pp in Q4; βˆ’1.2 pp FY; Marlboro premium share 59.4% FY (+0.1 pp). Basic share +1.9 pp YoY in Q4.
  • ABI adjusted equity earnings $161M in Q4 (+1.3% YoY).
  • Recorded $1.3B non-cash impairment of e-vapor intangibles and goodwill; e-vapor now a reportable segment.

Capital & Funding

  • Returned ~$8B to shareholders in FY25 (dividends + buybacks).
  • Paid $7B in dividends; dividend raised 3.9% in August (60th increase in 56 years).
  • Repurchased >17M shares for $1B; $1B remains under $2B program through 2026.
  • Total debt to EBITDA ~2.0x at year-end, at target.

Operations & Strategy

  • Maintaining measured e-vapor investment until enforcement and FDA authorization pace improve; NJOY ACE not expected to return in 2026.
  • Building PM USA cigarette import/export capabilities; benefits expected to build through 2H 2026.
  • Deploying RGM to support Basic in price-sensitive stores while minimizing impact to Marlboro.
  • Focusing on pouch innovation (formats, flavors, strengths); drive ON PLUS trial and retain ON Classic users in 2026.
  • Advocating stronger enforcement against illicit e-vapor and faster FDA authorizations (incl. Pollak program).

Market & Outlook

  • U.S. e-vapor category +~30% in 2025; ~70% illicit flavored disposables; >20M vapers (~15M disposable users).
  • Disposable e-vapor growth moderating: volumes +~30% in 2025 vs >50% in 2024; user growth +~10% vs >40%.
  • Cross-category impact on cigarette decline revised to ~2%–3% (from 3%–4%).
  • Nicotine pouches now ~57% of oral tobacco; competitors’ pricing βˆ’12% YoY in Q4 amid elevated promotions; ON prices +4% sequentially and +3% YoY.
  • FY26 adjusted EPS guidance $5.56–$5.72; growth weighted to 2H; assumes limited near-term enforcement impact, continued investment in contract manufacturing, and NJOY ACE not in market.

Risks Or Headwinds

  • Persistent illicit flavored disposable e-vapor presence (~70% of category) and uncertain enforcement timing.
  • Regulatory approval pace and IP constraints in e-vapor.
  • Cigarette volume declines (industry βˆ’8% FY) and consumer trade-down to discount segment pressuring Marlboro share.
  • Elevated competitive promotions and pricing pressure in nicotine pouches.
  • Higher manufacturing costs from import/export capability investments.
  • E-vapor impairment ($1.3B) reflects slower-than-expected enforcement progress; NJOY ACE absence in 2026.

Sentiment: MIXED

Note: This summary was synthesized by AI from the MO Q4 2025 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

Fundamentals Overview

Loading fundamentals overview...

πŸ“Š AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2025-12-31

"Altria Group reported Q4 2025 revenue of $5.85 billion and net income of $1.12 billion, with an EPS of $0.66. The company's free cash flow stood at $3.18 billion, demonstrating resilience and capability in generating cash. On a year-over-year basis, the earnings reflect stable performance despite the challenging market conditions. Growth was modest, driven primarily by robust operating cash flows and effective cost management, though overall revenue showed limited expansion. Profit margins remain healthy, supported by strong operational efficiency and a consistent EPS trend. Free cash flow was strong, covering dividends and allowing for share repurchases, reflecting efficient capital allocation. Leverage remains high with net debt at $21.23 billion and negative equity of $3.45 billion, indicating financial risk but manageable given the cash flow generation. Analyst sentiment suggests a moderate outlook with price targets peaking at $68 and a consensus at $60.67, reflecting cautious optimism. Dividends, with a quarterly payout increasing from $1.02 to $1.06, bolster long-term shareholder returns."

Revenue Growth

Fair

Revenue growth remains modest with limited expansion in top-line figures. Stability comes from core business performance.

Profitability

Good

Healthy net margin and EPS reflect robust cost management and operational efficiency.

Cash Flow Quality

Strong

Strong free cash flow supports dividends and buybacks, indicating solid liquidity and capital allocation.

Leverage & Balance Sheet

Neutral

High net debt and negative equity suggest financial vulnerability, though offset by strong cash generation.

Shareholder Returns

Good

Attractive dividend yield and share buybacks contribute positively to shareholder value.

Analyst Sentiment & Valuation

Positive

Moderate consensus price target reflects cautious market sentiment with potential upside.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

Loading financial data and tables...
πŸ“

SEC Filings (MO)

Β© 2026 Stock Market Info β€” Altria Group, Inc. (MO) Financial Profile